Molecular shuttle chelation: The use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum

Cellular and Molecular Neurobiology

Volumn 24, Issue 3, 2004, Pages 443-459

  Kruck, Theo P ^a   Cui, Jian Guo ^b   Percy, Maire E ^a   Lukiw, Walter J ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aluminum Al(III) ; Alzheimer's disease; Amyotrophic lateral sclerosis; Ascorbate; Chelation therapy; Desferrioxamine; Feralex G; Glucose transporter; molecular shuttle chelation; Nuclei; Vitamin C

Indexed keywords

ALUMINUM DERIVATIVE; ASCORBIC ACID; DEFEROXAMINE; FERALEX G; GLUCOSE TRANSPORTER; IRON DERIVATIVE; UNCLASSIFIED DRUG;

ALUMINUM CHELATION; ALUMINUM OVERLOAD; ARTICLE; BRAIN CELL; CELL NUCLEUS MEMBRANE; CHELATION THERAPY; CONTROLLED STUDY; ELUTION; HUMAN; HUMAN TISSUE; IRON CHELATION; LIGAND BINDING; MOLECULAR SHUTTLE CHELATION; PRIORITY JOURNAL; STOICHIOMETRY;

AGED; ALUMINUM; ASCORBIC ACID; BINDING SITES; BRAIN CHEMISTRY; CELL NUCLEUS; CHELATING AGENTS; CHELATION THERAPY; DEFEROXAMINE; DIFFUSION; DRUG SYNERGISM; HUMANS; MOLECULAR STRUCTURE; MONOSACCHARIDES; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONS; PYRIDONES; SUBCELLULAR FRACTIONS; TERMINOLOGY;

EID: 3342879300     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CEMN.0000022773.70722.b2     Document Type: Article

References (45)

1. Allen, D. D., Orvig, C., and Yokel, R. A. (1994). Pharmacokinetics and distribution of tris(maltolato) aluminum (III) into the central nervous system. Neurotoxicology 15:371-378.
2. Allen, T. D., Cronshaw, J. M., Bagley, S., Kiseleva, E., and Gordberg, M. W. (2000). The nuclear pore complex: Mediator of translocation between nucleus and cytoplasm. J. Cell Sci. 113:1651-1659.
3. Andrade, J. P., Cadete-Leite, A., Paula-Barbosa, M. M., Volk, B., and Tavares, M. A. (1988). Long-term alcohol consumption reduces the number of neuronal nuclear pores. A morphometric study undertaken in CA3 hippocampal pyramids of rats. Alcohol. Clin. Exp. Res. 12:286-289.
4. Blanusa, M., Prester, L., Varnai, V. M., Pavlovic, D., Kostial, K., Jones, M. M., and Singh, P. K. (2000). Chelation of aluminium by combining DF and L1 in rats. Toxicology 147:151-156.
5. Bouras, C., Giannakopoulos, P., Good, P. F., Hsu, A., Hof, P. R., and Perl, D. P. (1987). A laser microscope mass analysis of brain aluminum and iron in dementia pugilistica: Comparison with Alzheimer's disease. Eur. J. Neurol. 38:53-58.
6. Caravan, P., Rettig, S. J., and Orvig, C. (1997). Effect of pyridyl donors in the chelation of Al(III), gallium(III), and indium(III). Inorg. Chem. 36:1306-1315.
7. Carpenter, D. O. (2001). Effects of metals on the nervous system of humans and animals. Int. J. Occup. Med. Environ. Health 14:209-218.
8. Cherny, R. A., Barnham, K. J., Lynch, T., Volitakis, I., Li, Q. X., McLean, C. A., Multhaup, G., Beyreuther, K., Tanzi, R. E., Masters, C. L., and Bush, A. I. (2000). Chelation and intercalation: Complementary properties in a compound for the treatment of Alzheimer's disease. J. Struct. Biol. 130:209-216.
9. CIBA-GEIGY Limited (1989). Technical Bulletin 992 810.5-957/2, CIBA-GEIGY Limited, Basel, Switzerland.
10. Crapper, D. R., Quittkat, S., Krishnan, S. S., Dalton, A. J., and de Boni, U. (1980). Ultranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy and experimental aluminum encephalopathy. Acta Neuropathol. 50:19-24.
11. Cuajungco, M. P., Faget, K. Y., Huang, X., Tanzi, R. E., and Bush, A. I. (2000). Metal chelation as a potential therapy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 920:292-304.
12. Exley, C. A. (1999). A molecular mechanism of aluminium-induced Alzheimer's disease. J. Inorg. Biochem. 76:133-140.
13. Exley, C., and Korchazhkina, O. (2001). The association of Al and β-amyloid in Alzheimer's disease. In Exley, C. (ed.), Al and Alzheimer's Disease, The Science That Describes the Link, Elsevier, New York, pp. 421-433.
14. Gelles, J., and Landick, R. (1998). RNA polymerase as a molecular motor. Cell 93:13-16.
15. 3+ and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91:4902-4906.
16. Joshi, J. G. (1991). Neurochemical hypothesis: participation by Al in producing critical mass of colocalized errors in brain leads to neurological disease. Comp. Biochem. Physiol. 100:103-105.
17. Kontoghiorghes, G. J. (1995). New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. Analyst 120:845-851.
18. Kruck, T. P. A., and Burrow, T. E. (2002). Synthesis of Feralex-G: A novel aluminum/iron chelating compound. J. Inorg. Biochem. 88:19-24.
19. Kruck, T. P. A., Krishnan, S. S., McLachlan, D. R. C., and Percy, M. E. (2002). Intramuscular injection of desferrioxamine lowers brain Al concentration in patients with Alzheimer's disease. In Khassanova, L., Collery, P. H., Maymard, I., Khassanova, Z., and Etienne, J. C. (eds.), Metal Ions in Biology and Medicine, Vol. 7, John Libbey Eurotext, Paris, pp. 189-192.
20. Kruck, T. P. A., and McLachlan, D. R. (1989). Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: Ion specific chelation. Prog. Clin. Biol. Res. 317:1155-1167.
21. Lillie, R. D., Donaldson, P., Jirge, S. K., and Pizzolato, P. (1976). Iron and aluminum lakes of Gallo blue E as nuclear and metachromatic mucin stains. Stain Technol. 51:187-192.
22. Lovell, M. A., Ehmann, W. D., and Markesbery, W. R. (1993). Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann. Neurol. 33:36-42.
23. Lukiw, W. J. (1997). Aluminum in Alzheimer's Disease. In Yasui, M., Strong, M., Ota, K., and Verity, M. A. (eds.), Mineral and Metal Neurotoxicology, CRC Press, Boca Raton, FL, pp. 113-126.
24. Lukiw, W. J. (2001). Al and gene transcription in the mammalian central nervous system. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 47-68.
25. Lukiw, W. J., Bergeron, C. Wong, L., Kruck, T. P. A., Krishnan, B., and McLachlan, D. R. C. (1992). Nuclear compartmentalization of aluminum in Alzheimer's disease. Neurobiol. Aging 13:115-121.
26. Lukiw, W. J., Kruck, T. P. A., and McLachlan, D. R. (1989). Aluminum, intracellular liganding and the nucleus. Lancet 1:781.
27. Lukiw, W. J., LeBlanc, H. J., Carver, L. A., McLachlan, D. R., and Bazan, N. G. (1998). Run on transcription in human neocortical nuclei-inhibition by nanomolar aluminum and implications for neurodegenerative disease. J. Mol. Neurosci. 11:67-78.
28. Lukiw, W. J., St. George-Hyslop, P., and McLachlan, D. R. C. (1994). Chromatin structure, nuclear aluminum and gene expression in Alzheimer's disease. In Basic and Clinical Aspects of Neuroscience, Regulation of Gene Expression and Brain Function. Sandoz Publications, Basel, Switzerland, pp. 31-45.
29. Macdonald, T. L., and Martin, R. B. (1998). Aluminum ion in biological systems. Trends Biochem. Sci. 13:15-19.
30. Martin, R. B. (1992). Aluminium speciation in biology. Ciba Found. Symp. 169:5-18.
31. Murayama, H., Shin, R. R., Higuchi, J., Shibuya, S., Muramoto, T., and Kitamoto, T. (1999). Interaction of Al with PHF tau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Am. J. Pathol. 155:877-885.
32. Pante, N., and Kann, M. (2002). The nuclear pore complex is able to transport macromolecules with diameters of ∼39 nm. Mol. Biol. Cell 13:425-434.
33. Perl, D. P. (2001). The association of Al and neurofibrillary degeneration in Alzheimer's disease, a personal perspective. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 133-146.
34. Perl, D. P., Gajdusek, D. C., Garruto, R. M., Yanagihara, R. T. and Gibbs, C. J. (1982). Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science 217:1053-1055.
35. Pratico, D., Uryu, K., Sung, S., Tang, S., Trojanowski, J. Q., and Lee, V. M.-Y. (2002). Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16:1138-1140.
36. Rondeau, V. and Commenges, D. (2001). The epidemiology of Al and Alzheimer's disease. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 37-57.
37. Shin, R.-W. (2001). Al, tau and neurofibrillary degeneration. In Exley, C. (ed.), Al and Alzheimer's Disease, the Science That Describes the Link, Elsevier, New York, pp. 411-420.
38. Shin, R. W., Kruck, T. P. A., Murayama, H., and Kitamoto, K. (2003). A novel trivalent cation chelator Feralex-G dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res. 961:139-46.
39. Thompson, R. J. (1973). Studies on RNA synthesis in two populations of nuclei from the mammalian cerebral cortex. J. Neurochem. 21:19-40.
40. Yokel, R. A. (1994). Al chelation: Chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine. J. Toxicol. Environ. Health 41:131-174.
41. Yokel, R. A. (2002). Aluminum-chelation principles and recent advances. In Zatta, P. (ed.), Recent Topics in Aluminum Chemistry, Vol. 228: Coordination Chemistry Reviews, Elsevier, New York, pp. 97-113.
42. Yokel, R. A., Ackrill, P., Burgess, E., Day, J. P., Domingo, J. L., Platen, T. P., and Savory, J. (1996). Prevention and treatment of Al toxicity including chelation therapy: Status and research needs. J. Toxicol. Environ. Health 48:667-683.
43. Yokel, R. A., Rhineheimer, S. S., Sharma, P., Elmore, D., and McNamara, P. J. (2001). Entry, half-life, and desferrioxamine-accelerated clearance of brain Al after a single (26)Al exposure. Toxicol. Sci. 64:77-82.
44. Yoshida, S. (1991). Environmental factors in western Pacific foci of ALS and a possible pathogenetic role of aluminum (Al) in motor neuron degeneration. Rinsho Shinkeigaku 31:1310-1312.
45. Yoshida, S., Mitani, K., Wakayama, I., Kihira, T., and Yase, Y. (1995). Bunina body formation in amyotrophic lateral sclerosis: A morphometric- statistical and trace element study featuring aluminum. J. Neural. Sci. 130:88-94.